Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, People's Republic of China.
World J Surg Oncol. 2021 Nov 18;19(1):330. doi: 10.1186/s12957-021-02444-7.
HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1-4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC.
We presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After multiple lines of treatment, he obtained a durable response (10 months) to afatinib and anlotinib.
We reported for the first time that afatinib and anlotinib have successfully treated lung adenocarcinoma with HER2 p.Asp769Tyr mutation. This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.
HER2 是受体酪氨酸激酶 ERBB 家族的成员，HER2 突变作为致癌驱动突变发生在 1-4%的非小细胞肺癌（NSCLC）中。我们在 NSCLC 中发现了一种罕见的 HER2 p.Asp769Tyr 突变。
我们报告了一例 68 岁非吸烟男性患者，患有肺腺癌脑转移，携带罕见的 HER2 p.Asp769Tyr 突变。经过多线治疗，他对阿法替尼和安罗替尼均获得持久缓解（10 个月）。
我们首次报道阿法替尼和安罗替尼成功治疗了携带 HER2 p.Asp769Tyr 突变的肺腺癌。这一发现可以为新型突变的肺腺癌患者的最佳治疗提供思路。此外，我们在本文中总结了针对 HER2 突变型肺癌的靶向治疗疗效。
